Cybin Inc

This #Thanksgiving, at #Cybin we're grateful for the progress, partnerships, and possibilities that drive us forward. We're especially thankful for our world-class team of scientists and professionals working tirelessly to realize a mental health revolution. #Gratitude #MentalHealth

In our phase 2 study, both the 12 mg and 16 mg doses demonstrated highly statistically significant improvements in symptoms of depression of 13 to 14 points on the MADRS, when compared with placebo. With effect sizes greater than 2 for both doses, we are well positioned to commence our phase 3 program. Learn more: https://shorturl.at/Sijcc #BreakthroughTherapy #MentalHealth #Depression

#Cybin is anticipating important value-driving milestones across our pipeline in early 2025. We look forward to sharing the progress of our #PARADIGM Phase 3 program, as well as sharing topline efficacy data from our Phase 2 CYB004 study in #GAD in the first quarter 2025. Learn more: https://loom.ly/45YOW9g #Neuropsychiatry #MentalHealth #BreakthroughTherapy #depression

With infrequent acute dosing and long-lasting relief, CYB003 presents a unique opportunity to shift the paradigm of depression care by reducing the frequency of visits for existing patients and lowering barriers to timely care. Instead of masking symptoms, CYB003 addresses root causes. Learn more: https://loom.ly/45YOW9g #ParadigmShift #MentalHealth #BreakthroughTherapy #Depression

Our 12-month CYB003 Phase 2 data showed robust, sustained improvements in depression symptoms, durable response and remission rates, and a favourable safety and tolerability profile — heralding a potential #ParadigmShift in the treatment of Major Depressive Disorder (#MDD). Learn more: https://shorturl.at/2TC6e ↩️ #Neuropsychiatry #MentalHealth #Depression

Thanks for your support of the sector, Jake and Adam. Always enjoy our conversations.

Last week, #Cybin CEO Doug Drysdale discussed how our therapies induce neuroplasticity and new thought patterns for durable impacts on mental illness at a panel on the Next Frontier in Mental Health Research during the Milken Institute's Future of Health Summit. Watch the full session here: https://lnkd.in/guC5NFue ↩️ #Neuropsychiatry #MentalHealthInnovation #BreakthroughTherapy

#Cybin is thrilled to report positive Phase 2 data for CYB003, demonstrating #breakthrough efficacy in treating Major Depressive Disorder (#MDD).    100% of participants were responsive to treatment and 71% were in remission at 12 months after just two 16 mg CYB003 doses. Learn more: https://shorturl.at/z6jnL ↩️ #Neuropsychiatry #MentalHealthInnovation

#Cybin CEO Doug Drysdale discusses the impact of Robert F. Kennedy Jr.'s nomination as Secretary of U.S. Department of Health and Human Services (HHS) and the urgency of innovative therapies like ours to address the ongoing mental health crisis. #Neuropsychiatry #MentalHealthInnovation #RFK #BreakthroughTherapy

"The vast majority of patients on CYB003 in our Phase 2 study in both the 12mg and 16mg groups showed sustained improvements in symptoms of Major Depressive Disorder (#MDD), with unprecedented response and remission rates. After 2 doses of 12 mg, 60% of the patients were still responders after a year while 50% were in remission. After two doses of 16mg, 100% of participants were responders and 71% of participants were in remission. So both dose levels were effective at 12 months. If these figures hold true in Phase 3 — where 16mg doses will be our focus — they will truly transform the treatment landscape for MDD."    — #Cybin Chief Medical Officer Amir Inamdar MBBS, DNB (Psych), FFPM   Learn more about our 12-month efficacy data from Phase 2 of CYB003: our proprietary deuterated psilocin program in development for the potential adjunctive treatment of #MDD: https://shorturl.at/3aQnR ↩️   #Neuropsychiatry #MentalHealthInnovation #Depression